JDJulia Patricia Deisinger

Julia Patricia Deisinger

*This is an algorithmically generated author record based on publicly available information.

Julia Patricia Deisinger has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Streptomyces megacluster encodes synergistic biotin-targeting antibiotics

    by R. Gordzevich, M. Xu, W. Wang, M. A. Cook, D. Hackenberger, J. P. Deisinger, M. M. Tu, L. A. Carfrae, M. George, K. Rachwalski, et al.

    Natural products remain a major source of antibiotics, but discovery efforts have traditionally treated biosynthetic gene clusters as sources of individual bioactive molecules1-5. Increasing evidence has suggested that microorganisms can instead encode coordinated multi-metabolite systems, yet the genetic architectures and biological logic of such systems remain poorly understood6-12. Here we show that Streptomyces spp. encode a highly conserved biosynthetic megacluster that produces four structurally distinct natural product families-stravidins, acidomycin, dapamycins, and 2-methyl-7-keto-8-aminopelargonic acid (α-Me-KAPA)-alongside the biotin-binding protein streptavidin. These components converge on bacterial biotin metabolism through complementary mechanisms, including enzyme inhibition, prodrug activation, cofactor mimicry and biotin sequestration. The encoded metabolites are co-produced and act synergistically across Gram-negative and mycobacterial species, with stravidin S2 and α-Me-KAPA showing enhanced efficacy in combination in a mouse model of multidrug-resistant Escherichia coli infection. This megacluster reveals a genetically encoded chemical arsenal that functions as a naturally evolved combination therapy against a conserved metabolic pathway. More broadly, our findings suggest that higher-order biosynthetic architectures may represent an overlooked reservoir of antibiotic mechanisms and support a shift from discovering isolated natural products to reconstructing native synergistic systems.


  • Evaluation of Azithromycin-Bicarbonate against Multidrug-Resistant Pathogens in Topical Murine Models of Infection

    by Maya A. Farha, Megan M. Tu, Lindsey Carfrae, Ashelyn E. Sidders, Rodion Gordzevich, Adele Girgis-Gabardo, Julia P. Deisinger, J. Z. Alex Cheong, Ting Y. Wong, Mariel G. Escatte, et al.

    Multidrug-resistant pulmonary infections pose significant therapeutic challenges as treatment options continue to dwindle in the face of rising antimicrobial resistance. Similar challenges arise in the management of wound infections such as those resulting from burn and blast injuries, where resistant pathogens severely limit treatment options. These wounds are further complicated by high microbial loads that exacerbate tissue damage, delay healing, and increase the risk of systemic infection. The escalating threat of antimicrobial resistance highlights the urgent need for innovative therapeutic strategies. This study evaluates the therapeutic potential of a novel topical formulation, azithromycin-bicarbonate (AZM-BIC), for addressing drug-resistant infections in both pulmonary and wound settings. Using murine models of infection in bicarbonate-depleted environments, including lung, blast injury, and burn wound models, topical administration of AZM-BIC enabled the localized delivery of therapeutic concentrations of bicarbonate. In the pulmonary model, AZM-BIC significantly reduced the bacterial burden. In vitro and ex vivo studies revealed AZM-BIC's ability to inhibit biofilm formation, a critical factor in managing chronic infections. In wound infection models, AZM-BIC reduced the bacterial burden and enhanced wound healing. These findings establish AZM-BIC as a promising therapeutic approach, offering a targeted, effective solution for pulmonary infection management and wound care amid the growing threat of antimicrobial resistance. Furthermore, given that azithromycin is a well-established antibiotic and bicarbonate is a physiological component that is safe and well-tolerated, AZM-BIC represents a readily translatable strategy for clinical implementation.


  • Open Access

    High-Throughput Discovery of Synthetic Siderophores for Trojan Horse Antibiotics

    by Brent S. Weber, Nikki E. Ritchie, Simon Hilker, Derek C. K. Chan, Carsten Peukert, Julia P. Deisinger, Rowan Ives, Christine Årdal, Lori L. Burrows, Mark Brönstrup, et al.

    To cause infection, bacterial pathogens must overcome host immune factors and barriers to nutrient acquisition. Reproducing these aspects of host physiology in vitro has shown great promise for antibacterial drug discovery. When used as a bacterial growth medium, human serum replicates several aspects of the host environment, including innate immunity and iron limitation. We previously reported that a high-throughput chemical screen using serum as the growth medium enabled the discovery of novel growth inhibitors overlooked by conventional screens. Here, we report that a subset of compounds from this high-throughput serum screen display an unexpected growth enhancing phenotype and are enriched for synthetic siderophores. We selected 35 compounds of diverse chemical structure and quantified their ability to enhance bacterial growth in human serum. We show that many of these compounds chelate iron, suggesting they were acting as siderophores and providing iron to the bacteria. For two different pharmacophores represented among these synthetic siderophores, conjugation to the β-lactam antibiotic ampicillin imparted iron-dependent enhancement in antibacterial activity. Conjugation of the most potent growth-enhancing synthetic siderophore with the monobactam aztreonam produced MLEB-22043, a broad-spectrum antibiotic with significantly improved activity against Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa. This synthetic siderophore-monobactam conjugate uses multiple TonB-dependent transporters for uptake into P. aeruginosa. Like aztreonam, MLEB-22043 demonstrated activity against metallo-β-lactamase expressing bacteria, and, when combined with the β-lactamase inhibitor avibactam, was active against clinical strains coexpressing the NDM-1 metallo-β-lactamase and serine β-lactamases. Our work shows that human serum is an effective bacterial growth medium for the high-throughput discovery of synthetic siderophores, enabling the development of novel Trojan Horse antibiotics.


  • Open Access

    Dual targeting of the class V lanthipeptide antibiotic cacaoidin

    by Julia P. Deisinger, Melina Arts, Ioli Kotsogianni, Jan-Samuel Puls, Fabian Grein, Francisco Javier Ortiz-López, Nathaniel I. Martin, Anna Müller, Olga Genilloud, Tanja Schneider


  • Open Access

    Host Defense Peptides: Dual Antimicrobial and Immunomodulatory Action

    by Matthew Drayton, Julia P. Deisinger, Kevin C. Ludwig, Nigare Raheem, Anna Müller, Tanja Schneider, Suzana K. Straus

    The rapid rise of multidrug-resistant (MDR) bacteria has once again caused bacterial infections to become a global health concern. Antimicrobial peptides (AMPs), also known as host defense peptides (HDPs), offer a viable solution to these pathogens due to their diverse mechanisms of actions, which include direct killing as well as immunomodulatory properties (e.g., anti-inflammatory activity). HDPs may hence provide a more robust treatment of bacterial infections. In this review, the advent of and the mechanisms that lead to antibiotic resistance will be described. HDP mechanisms of antibacterial and immunomodulatory action will be presented, with specific examples of how the HDP aurein 2.2 and a few of its derivatives, namely peptide 73 and cG4L73, function. Finally, resistance that may arise from a broader use of HDPs in a clinical setting and methods to improve biocompatibility will be briefly discussed.


  • Open Access

    Frontispiz: Cacaoidin, First Member of the New Lanthidin RiPP Family

    by Francisco Javier Ortiz‐López, Daniel Carretero‐Molina, Marina Sánchez‐Hidalgo, Jesús Martín, Ignacio González, Fernando Román‐Hurtado, Mercedes de la Cruz, Sergio García‐Fernández, Fernando Reyes, Julia Patricia Deisinger, et al.


  • Top Cited Papers
    Open Access

    ATP-Dependent Persister Formation in Escherichia coli

    by Yue Shan, Autumn Brown Gandt, Sarah E. Rowe, Julia P. Deisinger, Brian P. Conlon, Kim Lewis

    Persisters are dormant variants that form a subpopulation of cells tolerant to antibiotics. Persisters are largely responsible for the recalcitrance of chronic infections to therapy. In Escherichia coli , one widely accepted model of persister formation holds that stochastic accumulation of ppGpp causes activation of the Lon protease that degrades antitoxins; active toxins then inhibit translation, resulting in dormant, drug-tolerant persisters. We found that various stresses induce toxin-antitoxin (TA) expression but that induction of TAs does not necessarily increase persisters. The 16S rRNA promoter rrnB P1 was proposed to be a persister reporter and an indicator of toxin activation regulated by ppGpp. Using fluorescence-activated cell sorting (FACS), we confirmed the enrichment for persisters in the fraction of rrnB P1 -gfp dim cells; however, this is independent of toxin-antitoxins. rrnB P1 is coregulated by ppGpp and ATP. We show that rrnB P1 can report persisters in a relA / spoT deletion background, suggesting that rrnB P1 is a persister marker responding to ATP. Consistent with this finding, decreasing the level of ATP by arsenate treatment causes drug tolerance. Lowering ATP slows translation and prevents the formation of DNA double-strand breaks upon fluoroquinolone treatment. We conclude that variation in ATP levels leads to persister formation by decreasing the activity of antibiotic targets. IMPORTANCE Persisters are a subpopulation of antibiotic-tolerant cells responsible for the recalcitrance of chronic infections. Our current understanding of persister formation is primarily based on studies of E. coli . The activation of toxin-antitoxin systems by ppGpp has become a widely accepted model for persister formation. In this study, we found that stress-induced activation of mRNA interferase-type toxins does not necessarily cause persister formation. We also found that the persister marker rrnB P1 reports persister cells because it detects a drop in cellular ATP levels. Consistent with this, lowering the ATP level decreases antibiotic target activity and, thus, leads to persister formation. We conclude that stochastic variation in ATP is the main mechanism of persister formation. A decrease in ATP provides a satisfactory explanation for the drug tolerance of persisters, since bactericidal antibiotics act by corrupting energy-dependent targets.